Why Effective Patent Life Is the Only Number That Matters Every pharmaceutical deal, licensing negotiation, and portfolio valuation ultimately hinges […]
1. Why API Supplier Selection Is an IP and Valuation Decision, Not a Procurement Function Most pharmaceutical procurement teams still
Section 1: What Freedom to Operate Actually Means — and What It Does Not 1.1 The Core Definition Freedom to
The $300 Billion Map: Why the Patent Cliff Is Your Best Market Signal {#market-signal} A drug patent is two things
Section 1: The Strategic Foundations of Pharmaceutical Pricing The price of a new drug is not calculated. It is constructed.
Executive Summary The pharmaceutical industry, characterized by its extensive research and development cycles, high investment costs, and intense competition, operates
A deep-dive for pharma/biotech IP teams, portfolio managers, R&D leads, and institutional investors who need to move beyond 71% forecast
1. The Market Context: A $400 Billion Patent Cliff and What It Means for Generic Entrants Between 2025 and 2030,
The patent cliff is not a metaphor. It is a measurable revenue event. When a branded drug loses market exclusivity,
Get fresh news and insights, drug patent expirations & more…
